Effective Treatment for Gastric Cancer with Peritoneal Metastasis

A study examined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) using paclitaxel and cisplatin in 22 patients with gastric cancer and peritoneal metastasis. Results showed that this treatment was well-tolerated with favorable oncologic outcomes. Patients experienced high rates of complete cytoreduction and R0 resection, and the treatment led to promising survival rates. Major complications were limited, and no deaths occurred within 90 days of the procedure. This approach shows promise in improving the prognosis for gastric cancer patients with peritoneal metastasis.